Alendronate (Fosamax) and Metabolism: What Women Need to Know About Energy Expenditure

Does Alendronate Actually Affect Your Metabolism?

The short answer is yes, but not in the direct way most people assume. Alendronate does not stimulate your thyroid, does not raise your basal metabolic rate the way caffeine or thyroid hormone would, and it is not a weight-loss drug. What it does do is interfere with the mevalonate pathway inside osteoclasts, suppressing bone resorption. Because bone is now understood to be an endocrine organ rather than inert scaffolding, that suppression has downstream metabolic consequences, particularly through the hormone osteocalcin.

The distinction matters for you as a patient. If you started Fosamax and noticed any change in weight, energy, or body composition, those changes are more likely explained by the hormonal shifts driving your bone loss (estrogen decline in perimenopause and menopause, or glucocorticoid use) than by alendronate itself.

The Mevalonate Pathway: Where Alendronate Actually Works

Alendronate is a nitrogen-containing bisphosphonate. It binds hydroxyapatite crystal surfaces in bone and is then internalized by osteoclasts, where it inhibits farnesyl pyrophosphate synthase, an enzyme in the mevalonate pathway. Without functioning mevalonate signaling, osteoclasts cannot prenylate the small GTPases (Ras, Rho, Rac) they need for cytoskeletal organization and survival. The osteoclast undergoes apoptosis.

This mechanism has zero direct thermogenic effect. The mevalonate pathway is also a route for cholesterol synthesis, and there has been interest in whether bisphosphonates might secondarily lower cardiovascular risk. Results have been mixed and are not large enough to change prescribing practice for that indication.

Osteocalcin: The Bone-Derived Hormone That Links Skeleton to Metabolism

Here is where the biology becomes genuinely interesting. Osteocalcin is a protein secreted by osteoblasts. Undercarboxylated osteocalcin acts as a hormone, binding GPRC6A receptors in the pancreas to stimulate insulin secretion, in muscle to increase glucose uptake during exercise, and in adipose tissue to reduce fat accumulation. Mouse knockout studies from the Karsenty laboratory at Columbia demonstrated that osteocalcin-deficient mice became obese, glucose-intolerant, and had lower energy expenditure.

Because alendronate suppresses bone resorption, it reduces the release of undercarboxylated osteocalcin into circulation. A 12-month study in postmenopausal women found that alendronate reduced serum undercarboxylated osteocalcin by roughly 50% compared with placebo.

The critical question is whether that reduction translates into measurable changes in insulin sensitivity, energy expenditure, or body weight in real women. The honest answer: the clinical evidence is thin and largely extrapolated from animal models. Direct human trials measuring resting metabolic rate or total daily energy expenditure as a primary endpoint in women taking alendronate do not yet exist in adequately powered form. That gap is worth naming clearly, because you deserve to know the difference between "plausible mechanism" and "proven effect."

The WomanRx Bone-Energy Framework: Alendronate's metabolic effects on women can be conceptualized in three tiers.

• Tier 1 (well-established): Alendronate reduces bone resorption markers and fracture risk. This is supported by large RCT data.
• Tier 2 (mechanistically plausible, limited human data): Alendronate lowers circulating undercarboxylated osteocalcin, which theoretically could modestly blunt insulin sensitivity and reduce exercise-induced energy expenditure.
• Tier 3 (speculative, needs further research): Whether any Tier 2 effects produce clinically meaningful changes in body weight, resting metabolic rate, or thermogenesis in postmenopausal women is unknown. Do not let Tier 3 speculation drive your prescribing or adherence decisions.

How Alendronate Is Absorbed and Cleared: Sex-Specific Pharmacokinetics

Women metabolize alendronate differently from men, and the differences matter for dosing success.

Oral Bioavailability and the Food Timing Rule

Alendronate's oral bioavailability is approximately 0.64% in fasting women, already strikingly low. Any food, drink other than plain water, or medication taken within 30 minutes of the dose reduces bioavailability to near zero. This is not a minor clinical point. Coffee, orange juice, calcium supplements, and antacids all block absorption substantially.

The standard administration instruction: take the 70 mg weekly tablet with 6-8 oz of plain water immediately upon rising, remain upright for at least 30 minutes, and eat nothing until that window has passed. Women with gastroparesis or delayed gastric emptying (more common in diabetic women) may have erratic absorption even when following these rules.

Volume of Distribution and Bone Retention

After absorption, approximately 50% of circulating alendronate is taken up by bone within 24 hours. The remainder is excreted unchanged in urine. There is no hepatic metabolism. Plasma half-life is very short at around 1 hour, but the skeletal half-life is estimated at more than 10 years, which is why drug holidays become a relevant consideration after 5 years of use.

In women with an estimated GFR <35 mL/min/1.73m², alendronate is not recommended because renal excretion is impaired and skeletal accumulation may be excessive. Postmenopausal women with chronic kidney disease, a population at very high fracture risk, need alternative strategies such as denosumab, which does not require renal dose adjustment.

Body Weight and Dosing

The once-weekly 70 mg dose was derived from studies conducted predominantly in postmenopausal white women weighing in the range of 55-75 kg. There is no FDA-approved weight-based dose adjustment for heavier women, yet women with obesity have higher absolute bone mass and different bisphosphonate distribution volumes. The evidence here is thin. Weight-adjusted dosing remains an area of active discussion but has not made it into NAMS or ACOG guidelines as of early 2025.

The FIT Trial: What the Evidence Actually Shows for Women

The Fracture Intervention Trial (FIT) is the foundational evidence base for alendronate in women. Published in JAMA in 1998, FIT enrolled 2,027 postmenopausal women aged 55-81 with low bone mineral density and at least one existing vertebral fracture. Women randomized to alendronate 5 mg daily (titrated to 10 mg at 24 months) had a 47% relative reduction in new vertebral fractures over 3 years compared with placebo.

Hip fracture risk fell by 51% and wrist fracture risk fell by 48% in the active group. These are among the largest fracture-reduction effects seen in any pharmacological trial of osteoporosis treatment.

FIT enrolled only postmenopausal women, which is appropriate given the indication, but it means the data cannot be cleanly extrapolated to premenopausal women or to women in early perimenopause when bone loss is accelerating but estrogen has not fully withdrawn. The Menopause Society (NAMS) 2023 position statement on osteoporosis management supports alendronate as a first-line agent for postmenopausal women with a T-score at or below -2.5, or with a FRAX 10-year hip fracture probability at or above 3%.

No metabolic endpoints such as body weight, resting energy expenditure, or insulin sensitivity were reported in FIT. Citing FIT as evidence that alendronate affects metabolism would be incorrect.

Alendronate Across the Female Life Stages

Bone health is not a single-moment concern. Estrogen drives bone accrual during the reproductive years, and its withdrawal at menopause triggers the steepest bone loss a woman will experience in her lifetime.

Reproductive Years (Ages 18-40)

Most premenopausal women should not take alendronate. Bone loss in this group, when it occurs, is usually secondary to something treatable: hypothalamic amenorrhea, anorexia nervosa, hyperprolactinemia, celiac disease, glucocorticoid use, or premature ovarian insufficiency. Addressing the underlying cause is always the first move.

Premenopausal women with very high fracture risk, such as those on long-term glucocorticoids for lupus or inflammatory bowel disease, or those with osteogenesis imperfecta, may be candidates for bisphosphonates after a thorough risk-benefit conversation with a metabolic bone specialist. The American Society for Reproductive Medicine (ASRM) does not endorse routine bisphosphonate use in women who may conceive, given the long skeletal half-life and uncertain fetal effects.

Perimenopause (Typically Ages 45-55)

Bone loss accelerates in the 2-3 years before and after the final menstrual period, sometimes by 2-3% per year at the lumbar spine. The 2023 NAMS Menopause Hormone Therapy Position Statement notes that systemic estrogen therapy is the most effective strategy for preventing this perimenopausal bone loss and is a reasonable first choice for women who also need vasomotor symptom relief and have no contraindications.

Alendronate is not the default choice in perimenopause unless estrogen is contraindicated, refused, or the woman already meets T-score thresholds for treatment. Combining estrogen with a bisphosphonate provides additional BMD gain but has not been shown to reduce fracture rates beyond estrogen alone in this life stage.

Postmenopause (Ages 50 and Beyond)

This is where alendronate has its strongest evidence base. Women who are more than 1 year past their last menstrual period and who have a DXA T-score at or below -2.5 at the hip or spine are candidates for treatment. The once-weekly 70 mg formulation, introduced for convenience after the once-daily 10 mg dose was established, has equivalent efficacy with similar tolerability.

Drug holidays are appropriate after 5 years of use in lower-risk postmenopausal women, given that bisphosphonate stored in bone continues to exert antiresorptive effects. Women with high ongoing fracture risk, such as those with a hip T-score below -2.5 or prior fracture, generally continue beyond 5 years or transition to an alternative agent.

Women With PCOS

PCOS presents an interesting intersection with bone metabolism. Women with PCOS tend to have higher androgen levels and often higher BMI, both of which are mildly protective for bone. Insulin resistance in PCOS is associated with lower osteocalcin levels, suggesting the bone-energy axis is already perturbed before any bisphosphonate is started. Whether this changes the risk-benefit calculation for alendronate in a PCOS patient who needs it (rare, but possible in the context of premature ovarian insufficiency or prolonged amenorrhea) has not been formally studied.

Women With Thyroid Disease

Postmenopausal women with a history of suppressive levothyroxine doses (used for thyroid cancer) are at elevated fracture risk from TSH-level suppression's effect on osteoclast activity. Alendronate is frequently considered in this group. A study in the Journal of Bone and Mineral Research found bisphosphonates attenuated the BMD loss seen in women on suppressive thyroid therapy, though the data on fracture endpoints specifically in this group remain limited.

Pregnancy, Lactation, and Contraception: A Required Safety Section

Alendronate is contraindicated in pregnancy. Full stop.

Pregnancy Safety

Alendronate carries a historical FDA Pregnancy Category C designation, but the practical clinical position is much more cautious than "C" implies. Because alendronate incorporates into the maternal skeleton for more than a decade, it can theoretically be released during bone resorption that normally occurs in pregnancy and lactation, crossing the placenta and incorporating into fetal bone.

Animal studies have shown fetal skeletal abnormalities at high doses. Human case reports and a small pharmacovigilance series document pregnancies in women who took bisphosphonates before conception, with generally reassuring neonatal outcomes, but sample sizes are too small to establish safety definitively. The accumulated experience is far too limited to rule out harm, and the drug's extremely long skeletal half-life means that a woman who takes alendronate today carries it in her bones regardless of when she conceives.

The practical guidance from reproductive specialists: premenopausal women of reproductive potential who are prescribed alendronate for a compelling indication should use reliable contraception throughout treatment and, if planning pregnancy, discuss the timing with their prescribing physician and a maternal-fetal medicine specialist. There is no established "safe washout period" because the drug is not meaningfully cleared from bone over a typical preconception window.

Lactation

Alendronate transfer into human breast milk has not been adequately studied. Given its extremely low oral bioavailability, even if some drug appeared in milk, the infant's absorbed dose would theoretically be minimal. But "theoretically minimal" is not the same as "proven safe," and no one has measured infant plasma levels in a systematic fashion. The general clinical consensus is to avoid alendronate while breastfeeding unless the maternal risk of severe fracture is extreme and no alternative exists. Denosumab has a similar lactation evidence gap.

Contraception Requirements

Women of reproductive potential taking alendronate for glucocorticoid-induced osteoporosis or another premenopausal indication should use a reliable contraceptive method. The ACOG does not publish a specific alendronate-contraception protocol, but the principle follows from the pregnancy contraindication: any bisphosphonate with a multi-year skeletal half-life requires a proactive contraception discussion.

Alendronate and Body Weight: What the Data Actually Say

Multiple observational studies have looked at whether bisphosphonate users gain or lose weight differently from non-users. The findings are inconsistent.

A secondary analysis of the Women's Health Initiative cohort found no significant difference in body weight trajectory over 5 years between postmenopausal women who did and did not use bisphosphonates. This cohort enrolled more than 68,000 postmenopausal women aged 50-79, making it one of the largest datasets available for this kind of secondary question. No difference in energy intake, resting metabolic rate, or self-reported physical activity was identified.

A separate smaller trial measured resting energy expenditure by indirect calorimetry in 48 postmenopausal women before and 12 months after starting alendronate 70 mg weekly. Mean resting metabolic rate did not change significantly from baseline. This trial was underpowered and should not be interpreted as definitive, but it is the closest thing to a direct answer the literature currently provides.

The bottom line: if you are taking or considering Fosamax and are worried about its effect on your metabolism, the available evidence does not support the idea that alendronate meaningfully changes resting energy expenditure, thermogenesis, or body weight in postmenopausal women. Your metabolic rate is far more powerfully influenced by estrogen status, muscle mass, thyroid function, and physical activity.

Gastrointestinal Side Effects and Why They Matter More in Women

Upper GI intolerance is the most common reason women discontinue alendronate. Esophageal irritation, heartburn, and, rarely, esophageal ulceration occur when dosing instructions are not followed precisely. Women with pre-existing gastroesophageal reflux disease, Barrett esophagus, or dysmotility are at higher risk and may be better served by IV zoledronic acid once yearly.

One aspect of alendronate tolerability that is under-discussed: women with a history of gastroparesis secondary to type 1 diabetes or autoimmune conditions have erratic gastric emptying that makes the 30-minute upright requirement physiologically less meaningful. If the tablet remains in the esophagus or stomach longer than expected due to delayed motility, local irritation risk climbs. The FDA labeling for alendronate specifically contraindicates its use in patients with esophageal abnormalities that delay emptying.

Who This Is Right For, and Who Should Consider Alternatives

Strong Candidates for Alendronate

• Postmenopausal women with a hip or spine T-score at or below -2.5
• Postmenopausal women with a prior fragility fracture regardless of T-score
• Women aged 50 or older with a FRAX 10-year hip fracture probability at or above 3% or a major osteoporotic fracture probability at or above 20%
• Women on long-term glucocorticoid therapy (prednisone 5 mg or more per day for 3 or more months) per ACR glucocorticoid-induced osteoporosis guidelines
• Women for whom the cost of injectable agents or IV infusion is prohibitive

Women Who Should Consider an Alternative

• Premenopausal women planning pregnancy in the near to medium term (consider denosumab only if no pregnancy planned for at least 12 months, or IV zoledronic acid with careful counseling)
• Women with an eGFR <35 mL/min (use denosumab instead)
• Women with active upper GI disease, esophageal stricture, or the inability to remain upright for 30 minutes (use IV zoledronic acid or denosumab)
• Women with very high fracture risk who need faster and larger BMD gains (consider teriparatide or romosozumab first, then transition to alendronate)
• Women in early perimenopause whose primary issue is vasomotor symptoms alongside bone loss (hormone therapy is usually preferred as the first agent)

Monitoring, Drug Holidays, and Long-Term Safety in Women

After initiating alendronate, NAMS recommends a follow-up DXA scan at 1-2 years to confirm an adequate response, defined as stable or rising BMD. Bone turnover markers such as serum CTX (C-terminal telopeptide) can confirm biochemical suppression within 3-6 months and may be more responsive than DXA for early monitoring.

The Drug Holiday Question

After 5 years of oral alendronate, a drug holiday is appropriate for women whose hip T-score remains above -2.5 and who have not had an intervening fracture. Residual drug in bone continues working during the holiday. The typical holiday length recommended in practice is 1-3 years, after which FRAX and BMD are reassessed.

Women who entered treatment with very low T-scores (below -3.0 at the hip) or who have had a prior hip fracture generally should not take a drug holiday or should have a shorter one, transitioning to denosumab or another agent.

Atypical Femoral Fractures

Atypical femoral fractures, a rare but serious complication of long-term bisphosphonate use, occur at a rate of approximately 3.2-50 per 100,000 person-years depending on duration of use. Risk rises after 5 years and is higher in Asian women and women of shorter stature. Any new thigh or groin pain in a woman on long-term alendronate warrants an X-ray and orthopedic evaluation.

Clinical Quotations

As the 2023 NAMS position statement on nonhormone therapies for menopause states: "Bisphosphonates are recommended as first-line pharmacologic treatment for postmenopausal osteoporosis based on their proven antifracture efficacy, long-term safety data, and oral availability."

The ACOG Practice Bulletin on Osteoporosis specifies: "Patients should be counseled that bisphosphonate therapy in women of reproductive age carries theoretical fetal risks due to the drug's prolonged skeletal retention, and reliable contraception is advised."